CN101325951A - 富含亮氨酸的组合物 - Google Patents
富含亮氨酸的组合物 Download PDFInfo
- Publication number
- CN101325951A CN101325951A CNA2006800466429A CN200680046642A CN101325951A CN 101325951 A CN101325951 A CN 101325951A CN A2006800466429 A CNA2006800466429 A CN A2006800466429A CN 200680046642 A CN200680046642 A CN 200680046642A CN 101325951 A CN101325951 A CN 101325951A
- Authority
- CN
- China
- Prior art keywords
- compositions
- weight
- carbohydrate
- acid
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 title claims abstract description 18
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 60
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 60
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 48
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 150000002632 lipids Chemical class 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 4
- 235000018102 proteins Nutrition 0.000 claims description 58
- 235000014633 carbohydrates Nutrition 0.000 claims description 40
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 38
- 229940024606 amino acid Drugs 0.000 claims description 35
- 235000001014 amino acid Nutrition 0.000 claims description 35
- 150000001413 amino acids Chemical class 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 33
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 21
- 102000004877 Insulin Human genes 0.000 claims description 19
- 108090001061 Insulin Proteins 0.000 claims description 19
- 229940125396 insulin Drugs 0.000 claims description 19
- 230000015556 catabolic process Effects 0.000 claims description 17
- 235000005772 leucine Nutrition 0.000 claims description 17
- 210000003205 muscle Anatomy 0.000 claims description 17
- 235000019152 folic acid Nutrition 0.000 claims description 13
- 239000011724 folic acid Substances 0.000 claims description 13
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 12
- 229960000304 folic acid Drugs 0.000 claims description 12
- 150000003839 salts Chemical group 0.000 claims description 12
- 102000004407 Lactalbumin Human genes 0.000 claims description 11
- 108090000942 Lactalbumin Proteins 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 208000030507 AIDS Diseases 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- 150000002016 disaccharides Chemical class 0.000 claims description 9
- 229960000310 isoleucine Drugs 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 8
- 210000001198 duodenum Anatomy 0.000 claims description 7
- 210000003405 ileum Anatomy 0.000 claims description 7
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 235000020776 essential amino acid Nutrition 0.000 claims description 6
- 239000003797 essential amino acid Substances 0.000 claims description 6
- 150000002772 monosaccharides Chemical class 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 claims description 5
- 208000019693 Lung disease Diseases 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 230000002641 glycemic effect Effects 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 235000016804 zinc Nutrition 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 210000000941 bile Anatomy 0.000 claims description 3
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 235000020778 linoleic acid Nutrition 0.000 claims description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- -1 lysine amino acid Chemical class 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 102000008192 Lactoglobulins Human genes 0.000 claims description 2
- 108010060630 Lactoglobulins Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 150000002614 leucines Chemical class 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 235000010755 mineral Nutrition 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000010374 vitamin B1 Nutrition 0.000 claims description 2
- 239000011691 vitamin B1 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 108010073771 Soybean Proteins Proteins 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 235000019710 soybean protein Nutrition 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 230000002349 favourable effect Effects 0.000 description 9
- 102000011632 Caseins Human genes 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- YPMOAQISONSSNL-UHFFFAOYSA-N 8-hydroxyoctyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCO YPMOAQISONSSNL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000002639 Eukaryotic Initiation Factor-2B Human genes 0.000 description 1
- 108010082945 Eukaryotic Initiation Factor-2B Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 235000021290 n-3 DPA Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Polymers & Plastics (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
Abstract
本发明涉及包含蛋白质物质的组合物在制备用于治疗胰岛素耐受的药物中的用途,所述蛋白质物质提供所述组合物能量值的至少24.0%(en%)和基于蛋白质物质的至少12重量%的亮氨酸;并涉及适合于向哺乳动物给药的包含蛋白质部分、碳水化合物部分和脂质部分的组合物,其中所述蛋白质部分提供至少24.0%(en%),所述碳水化合物部分提供至多46en%,所述脂质部分提供至多30en%,且其中基于蛋白质物质,至少12重量%是亮氨酸。
Description
本发明涉及对罹患胰岛素耐受的个体的治疗,并涉及适合于这种目的或相关目的的组合物。
胰岛素耐受(IR)是机体丧失对胰岛素的敏感性。
创伤或疾病可能导致IR。例如,据报告严重烧伤事件导致IR。手术可能是另一诱因。在罹患各种疾病的患者中都观察到IR,例如在癌症末期患者中、艾滋病患者中、罹患慢性肺病的患者或罹患严重炎症的患者中都观察到IR。代谢综合征、糖尿病或肥胖也可能引起IR。衰老也可能导致IR。
胰岛素作用减弱影响肌肉、肝脏和胰腺中的糖代谢。本发明的发明人认识到胰岛素在人蛋白质代谢(特别是肌肉合成代谢或避免肌肉分解代谢)中发挥重要作用。具体而言,在罹患严重疾病例如艾滋病、慢性阻塞性肺病或癌症的患者中,IR可引起患者生存机会或预期寿命方面预后不良。而且,其可损害生命质量。
本发明的发明人还认识到,特别是在罹患代谢病症的患者中,IR导致的蛋白质代谢紊乱可引起瘦体重的降低。运动太少可使其恶化。例如,不活动的患者在肌肉量方面可能是严重分解代谢的。
本发明的目的是提供适合于治疗IR或IR相关症状的制剂。特别地,本发明的目的是提供用于该目的的药物组合物或食品组合物。
优选地,所述组合物应适合于治疗罹患IR的患者中的分解代谢,例如肌肉分解代谢。
优选地,感官特性应使食用通常被评价为令人愉快的。
优选地,所述组合物应易于通过胃。
优选地,所述组合物的可消化组分应在该产品被摄入后易于被利用。
在本发明的一方面,另一目的是增加个体对胰岛素的敏感性,且优选同时减少肌肉分解代谢。
在另一方面,本发明的目的是改善用所述组合物治疗的患者的预后和/或生命质量。
现已发现可能用包含蛋白质物质的特定组合物治疗罹患IR的个体。
因此,本发明涉及包含蛋白质物质的组合物在制备用于治疗罹患胰岛素耐受的个体(特别是用于治疗罹患胰岛素耐受的患者中的分解代谢病症)的药物中的用途,所述蛋白质物质提供所述组合物能量值的至少24.0%(en%)和基于蛋白质物质的至少12重量%的亮氨酸。所述分解代谢病症优选是肌肉分解代谢。
特别地,所述个体可以是罹患以下病症至少之一的个体:代谢病症,特别是代谢综合征、肥胖和/或糖尿病(包括I型糖尿病和II型糖尿病);癌症;艾滋病;阿尔茨海默病;心力衰竭;和严重炎症病症,特别是慢性肺病;关节炎,特别是风湿性关节炎;炎性肠病。
本发明还涉及适合于向哺乳动物给药的组合物,其包含蛋白质部分、碳水化合物部分和脂质部分,其中所述蛋白质部分提供至少24.0%(en%),所述碳水化合物提供至多46en%,所述脂质部分提供至多30en%,且其中基于蛋白质物质,至少12重量%是亮氨酸。
本发明可减轻至少一种与胰岛素耐受相关的症状。特别地,可减少蛋白质分解代谢,更特别是肌肉分解代谢。除增加蛋白质合成代谢以外,例如还可增加肌肉合成代谢。例如,在给药本发明中定义的药物/组合物之后可实现正性净蛋白质平衡持续至少一小时。在一个实施方案中,这对于罹患不期望的体重丧失(3个月内超过5%)的个体或者在有很大危险面临这种丧失的个体中、在面临创伤的个体中、在接受手术或接受影响较大的医学治疗(例如化疗或放疗)的个体中或者在罹患严重疾病的个体中、在长期不活动的个体中是可以实现的,其中所述个体已发生IR。
本发明提供更佳的预后,即延长的预期寿命和/或更佳的生命质量。改善生命质量的因素具体而言有较少疲劳、较多精力、较少并发症例如病毒感染和/或细菌感染(特别是口腔、咽喉、肠、伤口和肺内的感染)、减少视力丧失和/或听力丧失、更佳的总体状况和较少感觉抑郁的时间。
罹患IR的个体禁食后(例如在一夜睡眠后的清晨)血糖水平倾向于升高。具体而言,IR可由葡萄糖/胰岛素的HOMA比确定。Wallace等在DiabetesCare,Volume 27,Number 6,June 2004p 1487-1495中描述了HOMA建模。
蛋白质物质是由氨基酸形成的组分。本文使用的术语氨基酸包括氨基酸残基(例如在肽中)。具体而言,蛋白质物质包括游离氨基酸、氨基酸盐、与缀合分子和肽结合的氨基酸残基。肽包括寡肽以及蛋白质和其它多肽。同样,当提及特定氨基酸例如亮氨酸时,其意在包括盐形式、结合形式的该特定氨基酸(残基)以及游离的特定氨基酸。
化合物的能量值(en%)基于由该化合物的可消化部分(特别是在人或其它哺乳动物中)提供的能量。具体而言,能量值基于用以下换算因子所得的蛋白质物质、脂质和可消化碳水化合物的供量(contribution):可消化碳水化合物和蛋白质物质为4kcal/g,而脂质为9kcal/g。
可缓慢消化的碳水化合物的消化不如麦芽葡萄糖(maltodextrose)、麦芽糖和葡萄糖快。具体而言,在使用标准消化酶的分析装置中,若在20和120分钟内释放多于10%的糖(可根据恩奎斯特法(Enquist method)测定),则认为碳水化合物是可缓慢消化的。
快速消化的碳水化合物包括麦芽葡萄糖、麦芽糖或葡萄糖(可快速消化的碳水化合物)。具体而言,根据恩奎斯特法,在20分钟内多于90%的快速碳水化合物被消化。
低糖二糖(low glycemic disaccharides)特别是升糖指数<60的二糖(葡萄糖=100)。
在一个实施方案中,蛋白质物质的至少一部分以游离氨基酸、其盐或与非蛋白质或肽缀合分子的缀合物的形式存在,所述缀合物能够在胆汁组分和/或胰腺分泌物(excretia)的影响下在十二指肠和/或回肠中分裂成所述游离氨基酸(或其盐)和所述缀合化合物。在一个实施方案中,这种形式(特别是盐形式或游离形式)的氨基酸的量基于所述蛋白质物质至多为15重量%,优选为0.5-14重量%。
基于亮氨酸的总重,优选35-100重量%,更优选40-80重量%是肽(寡肽、多肽、蛋白质)形式的亮氨酸,优选是多肽和/或(完整)蛋白质形式的亮氨酸。因此,认为机体对亮氨酸的摄入比较慢,这对于治疗IR,特别是治疗罹患IR的患者中的(肌肉)分解代谢是有利的。
在优选的实施方案中,本发明(所使用的)组合物进一步包含在十二指肠和/或回肠中有效释放氨基酸的缓释制剂,所述制剂包含至少一种选自游离酸形式的氨基酸、盐形式的氨基酸和与非蛋白质缀合化合物的缀合物形式的氨基酸的组分,所述缀合物能够在胆汁组分和/或胰腺分泌物(excrements)的影响下在十二指肠和/或回肠中分裂成所述游离氨基酸(或其盐)和所述缀合化合物。
本发明的发明人已认识到这样这些游离氨基酸及其各自的盐可在十二指肠或回肠变得可被吸收,这与以多肽(包括蛋白质)形式提供的氨基酸变得可被吸收基本上同时发生或者更晚发生。特别地,对于必需氨基酸而言,认为这对于治疗IR(特别是治疗IR患者中的蛋白质(肌肉)分解代谢)是有利的。
缓释形式的氨基酸优选悬浮于液体、半液体或固体产品中。
缓释制剂可根据常规技术制备。氨基酸可用在十二指肠/回肠pH(约pH7)下溶解而在胃(强酸性)中不溶解的pH敏感材料包衣。这种包衣通常是本领域中已知的。缀合分子的实例为与所述氨基酸形成在生理条件下不被胃蛋白酶分裂或者至少不被其有效分裂的特定肽的分子。实例为胆碱、甜菜碱、二甲基甘氨酸和肌氨酸。其它合适的缀合分子包括磷脂、溶血磷脂(lyso-phospholipids)和甘油。
优选存在于所述缓释制剂中的氨基酸优选选自亮氨酸和其它必需氨基酸,特别是甲硫氨酸、精氨酸、色氨酸、苯丙氨酸和赖氨酸,其中特别优选亮氨酸。
在本发明(所使用的)组合物中,亮氨酸/(缬氨酸+异亮氨酸)的重量比通常为1.0或更高,优选为1.05或更高。
优选产品中的异亮氨酸的总量(重量)超过缬氨酸的总量(重量)。在所述组合物中通常存在的完整蛋白质不提供以上异亮氨酸与缬氨酸的重量比的情况下,则可以包含一种或多种化合物来影响异亮氨酸/缬氨酸比,所述化合物例如富含异亮氨酸且相对缺乏缬氨酸的肽,或者相对富含异亮氨酸的其它化合物,甚至是碱或盐形式的异亮氨酸(优选L-异亮氨酸)。
在整个产品中,必需氨基酸的含量通常为至少49重量%,优选49-80重量%,更优选52-70重量%的蛋白质物质由必需氨基酸形成。
赖氨酸含量通常为7.0-15g/100g蛋白质物质,优选7.5-14g/100g蛋白质物质。
在一个实施方案中,本发明(所使用的)组合物包含乳清蛋白部分,特别是基于蛋白质物质为至少10重量%,优选基于蛋白质物质为至少15重量%。通常,所述乳清蛋白组分基于蛋白质物质为50重量%或更少。特别地,在液体组合物的情况下,变性乳清蛋白的浓度基于蛋白质物质优选不超过35重量%。这对于避免贮存过程中发生胶凝作用的危险是有利的。
乳清蛋白的存在可提供很多优点。就释放速率和使必需氨基酸基本上在同时可被机体摄取两方面而言,乳清蛋白均显示有利的释放行为。这样用所述组合物治疗后可获得肌肉合成代谢程度。
(轻度)水解至少一部分乳清蛋白可进一步增强这种作用,所述水解的程度通常为至多20%的蛋白质被水解成游离氨基酸,优选的程度为至多10%的蛋白质被水解成游离氨基酸。
为了所述增强的作用,通常将50重量%或更少的乳清蛋白,特别是10-50重量%的乳清蛋白(轻度)水解。
若期望,可将游离氨基酸或其部分从水解产物中除去。合适的技术是已知的,例如过滤法、色谱法或吸收法。
作为乳清蛋白的来源,优选选择乳清蛋白部分包含少于20重量%的酪蛋白糖巨肽(GMP),更优选少于10g/100g蛋白质。
β-乳球蛋白含量优选高于40重量%,更优选46-80重量%。
酪蛋白可作为蛋白质物质存在。当以完整蛋白质形式使用时,酪蛋白优选包含高浓度的β酪蛋白,特别是多于36g/100g酪蛋白,更特别是38-70g/100g酪蛋白。
在本发明(所使用)的组合物中,脂质含量优选为至多30en%,更优选5-30en%,更优选5-29.0en%。
对于高品质的组合物,优选其提供充分的必需脂肪酸。为该目的,n-3与n-6多不饱和脂肪酸的比优选为至少0.2∶1至10∶1,更优选在0.4∶1至3∶1的范围内。在特别的实施方案中,该比为至少1.0。
脂质,特别是n-3和n-6多不饱和脂肪酸通常包括C18至C26脂肪酸。其优选的实例为α亚麻酸、二十碳五烯酸、二十二碳六烯酸、二十二碳五烯酸、亚油酸和花生四烯酸。
所述n-3多不饱和脂肪酸优选至少大部分选自α亚麻酸、二十碳五烯酸和二十二碳六烯酸。所述n-6多不饱和脂肪酸优选至少大部分选自亚油酸和花生四烯酸。
所述碳水化合物部分优选提供所述组合物的能量值中相对低的量,通常为46en%或更低。考虑治疗IR,认为这是有利的,因为餐后氨基酸反应(摄入所述组合物后血中可测量的氨基酸浓度)可能升高,这特别有助于减少IR症状,例如IR引起的肌肉分解代谢。
考虑以上,所述碳水化合物部分的含量优选提供总组合物的4-45.0en%,更优选8-44.0en%,更优选10-30en%。
本发明的发明人已进一步构想在摄入所述组合物后期望获得适度的胰岛素反应。所述组合物中存在的氨基酸(特别是游离氨基酸或其盐)的选择发挥一定作用。具体而言,精氨酸和赖氨酸对于胰岛素的释放具有刺激作用,因此优选不加入(游离形式或其盐形式)或者加入相对较低含量以减轻免疫应答。特别地,可以选择所述碳水化合物部分的组成以获得有利的碳水化合物摄取,并因此获得摄取后期望的胰岛素释放。因此,特别是碳水化合物含量满足以下标准中一项或多项的组成被认为是有利的。
在一个实施方案中,少于75重量%的碳水化合物由蔗糖和麦芽糖糊精的总和形成。
在一个实施方案中,基于所述碳水化合物的总重,至少40重量%由可缓慢消化的碳水化合物(即特别是其消化不如麦芽葡萄糖、麦芽糖和葡萄糖快的碳水化合物)形成。
在一个实施方案中,本发明(所使用的)组合物包含以所述碳水化合物的总重计少于60重量%,优选20-50重量%的可快速消化的碳水化合物,特别是麦芽葡萄糖、麦芽糖、葡萄糖和其消化至少同样快的其它碳水化合物。
在一个实施方案中,基于所述碳水化合物的总重,多于20重量%,优选22-60重量%由至少一种二糖形成。特别地,在这种实施方案中,所述二糖优选选自蔗糖、海藻糖、帕拉金糖(palatinose)、乳糖和其它低糖二糖,更优选选自海藻糖和帕拉金糖。
在一个实施方案中,存在至少一种非葡萄糖的单糖。优选地,所述单糖选自半乳糖、甘露糖和核糖。优选地,基于所述碳水化合物的总重,所述单糖的总量为0.5-30重量%,更优选5-25重量%。
特别地,存在核糖是有利的,优选与(内源)叶酸组合存在,以增加蛋白质合成。认为这两种化合物的组合可增加个体中鸟苷三磷酸的生成,通过刺激真核起始因子2B,特别是在营养不良患者中,导致蛋白质合成增加。
叶酸可以以下面一种或多种形式提供:游离叶酸、亚叶酸、甲酰化叶酸、甲基化叶酸,优选以还原形式或者单谷氨酸缀合或多谷氨酸缀合衍生物形式提供。
当存在时,叶酸含量通常为至少95μg/100kcal碳水化合物,优选110-400μg/100kcal碳水化合物,更优选125-300μg/100kcal碳水化合物。
除了叶酸之外,还可以加入一种或多种其它组分例如至少一种选自矿物质、微量元素和维生素的组分,优选选自维生素A、维生素C、维生素D、维生素E、维生素B6、维生素B1、维生素B2、生物素、硫辛酸、维生素B12和锌的组分。
这种组分可以至多推荐每日剂量/每日份量的浓度存在。
锌优选以至少2.8mg/100kcal碳水化合物,更优选5.6-20mg/100kcal碳水化合物,更优选6-15mg/100kcal碳水化合物的浓度存在。
在一个优选的实施方案中,以用药法给药本发明的组合物。具体而言,所述组合物可用作药物的辅剂,所述药物例如选自抗癌药、抗逆转录病毒药、抗高血压药、抗血栓药、抗抑郁药和抗糖尿病药的药物。特别地,将所述产品与二甲双胍或另一种抗糖尿病药一起使用是有利的。特别地认为这些药物在本发明的组合物中稳定并且非常有效。所述药物可存在于本发明的组合物中,或者可以单独给药。
本发明(所使用的)组合物的总能量值可在宽范围内选择。通常其为至少0.3kcal/ml,优选至少0.4kcal/ml,更优选至少0.5kcal/ml。一般而言,该值为至多2.0kcal/ml,例如1.58-2.0kcal/ml。但是优选能量密度的值为至多1.7kcal/ml,特别是至多0.9kcal/ml。在确定期望的能量值方面起作用的因素一方面包括容易获得较高en%蛋白质物质,另一方面包括快速的胃排空(增加合成代谢反应)。
在这方面,已发现能量值在0.5-0.9kcal/ml范围内的产品特别有利。另外,这种产品被消费者耐受的水平较高。
本发明还涉及用于治疗胰岛素耐受的方法,特别是治疗罹患IR的患者中的分解代谢症状的方法,其包括向个体给药包含蛋白质部分的组合物,所述蛋白质部分提供所述组合物能量值的至少24.0%(en%)和基于所述蛋白质物质的至少12重量%的亮氨酸。
本发明还涉及用于治疗由胰岛素耐受导致的肌肉分解代谢的方法,其包括向个体给药包含蛋白质部分的组合物,所述蛋白质部分提供所述组合物能量值的至少24.0%(en%)和基于所述蛋白质物质的至少12重量%的亮氨酸。
本发明还涉及本文所述的组合物用于改善生命质量,特别是用于改善不活动的人和/或老年人的生命质量的用途。
所述个体优选是人。
本发明的方法/组合物可特别地用于治疗罹患至少一种选自代谢综合征、糖尿病、肥胖、癌症、艾滋病、慢性肺病和严重炎症病症的病症的个体。
所述组合物优选是液体形式。
本发明(所使用的)组合物的一份剂量(serving size)优选为50-500g,更优选75-400g,更优选100-250g。所述组合物可以每日给药一次或每日给药几次。
所述组合物可经肠道给药。
Claims (39)
1.包含蛋白质物质的组合物在制备用于治疗罹患胰岛素耐受的个体的药物中的用途,所述蛋白质物质提供所述组合物能量值的至少24.0%(en%)和基于蛋白质物质的至少12重量%的亮氨酸。
2.权利要求1的用途,其中所述治疗旨在预防或降低由胰岛素耐受导致的肌肉分解代谢。
3.权利要求1或2的用途,其中所述个体罹患阿尔茨海默病;心力衰竭;和严重炎症病症,特别是慢性肺病;关节炎,特别是风湿性关节炎;炎性肠病;艾滋病和手术。
4.权利要求3的用途,其中所述个体罹患II型糖尿病。
5.适合于向哺乳动物给药的组合物,其包含蛋白质部分、碳水化合物部分和脂质部分,其中所述蛋白质部分提供至少24.0%(en%),所述碳水化合物提供至多46en%,所述脂质部分提供至多30en%,且其中基于蛋白质物质,至少12重量%是亮氨酸。
6.权利要求5的组合物,其中所述组合物还包含在十二指肠和/或回肠中有效释放氨基酸的缓释制剂,所述制剂包含至少一种选自游离酸形式的氨基酸、盐形式的氨基酸或与非蛋白质缀合化合物的缀合物形式的氨基酸的组分,所述缀合物能够在胆汁组分和/或胰腺分泌物的影响下在十二指肠和/或回肠中分裂成所述游离氨基酸(或其盐)和所述缀合化合物。
7.权利要求6的组合物,其中所述制剂包含至少一种选自亮氨酸、甲硫氨酸、精氨酸、色氨酸、苯丙氨酸和赖氨酸的氨基酸,优选选自亮氨酸、甲硫氨酸、色氨酸和苯丙氨酸的氨基酸,更优选为亮氨酸。
8.权利要求5-7之任一项的组合物,其中所述蛋白质部分的含量提供总组合物的24.0-70en%,优选25.0-50en%。
9.权利要求5-8之任一项的组合物,其中所述蛋白质部分包含至少一种选自乳清蛋白、大豆蛋白和酪蛋白的蛋白质,优选至少一种乳清蛋白,更优选β-乳球蛋白。
10.权利要求9的组合物,其中乳清蛋白的总量为所述蛋白质物质总重的至少10重量%,优选为所述蛋白质物质总重的15-35重量%。
11.权利要求5-10之任一项的组合物,其中所述脂质部分的含量提供总组合物的5-29en%。
12.权利要求5-11之任一项的组合物,其中所述脂质部分包含至少一种n-3多不饱和脂肪酸和至少一种n-6多不饱和脂肪酸,n-3多不饱和脂肪酸与n-6多不饱和脂肪酸的比(重量比重量)优选在0.2∶1至10∶1的范围内,更优选在0.4∶1至3∶1的范围内。
13.权利要求11或12的组合物,其包含至少一种具有18-26个碳原子的多不饱和脂肪酸,优选至少一种选自α亚麻酸、二十碳五烯酸、二十二碳六烯酸、亚油酸和花生四烯酸的多不饱和脂肪酸。
14.权利要求5-13之任一项的组合物,其中所述碳水化合物部分的含量提供总组合物的4-45en%,优选8-44en%,更优选10-30en%。
15.权利要求5-14之任一项的组合物,其中基于所述碳水化合物的总重,至少40重量%由可缓慢消化的碳水化合物即特别是其消化不如麦芽葡萄糖、麦芽糖和葡萄糖快的碳水化合物形成。
16.权利要求5-15之任一项的组合物,其包含以所述碳水化合物的总重计20-50重量%的可快速消化的碳水化合物,特别是麦芽葡萄糖、麦芽糖、葡萄糖和其它其消化速度至少同样快的碳水化合物。
17.权利要求5-16之任一项的组合物,其包含以所述碳水化合物的总重计多于20重量%,优选22-60重量%的至少一种二糖。
18.权利要求17的组合物,其中所述二糖选自蔗糖、海藻糖、帕拉金糖、乳糖和其它低糖二糖,优选选自海藻糖和帕拉金糖。
19.权利要求5-18之任一项的组合物,其包含至少一种非葡萄糖的单糖,例如至少一种选自半乳糖、甘露糖和核糖的单糖。
20.权利要求19的组合物,其中基于所述碳水化合物的总重,所述单糖的总量为0.5-30重量%,优选5-25重量%。
21.权利要求5-20之任一项的组合物,其中所述蛋白质物质的至少49重量%,优选49-80重量%,更优选52-70重量%由必需氨基酸形成。
22.权利要求5-21之任一项的组合物,其中所述组合物的能量值在0.3-2.0kcal/ml的范围内,优选在0.4-1.7kcal/ml的范围内,更优选在0.4-1.2kcal/ml的范围内,更优选在0.5-0.9kcal/ml的范围内。
23.权利要求5-22之任一项的组合物,其中亮氨酸/(缬氨酸+异亮氨酸)的重量比为1.0或更高,优选为1.05或更高。
24.权利要求5-23之任一项的组合物,其中赖氨酸含量为7.0-15g/100g蛋白质物质,优选7.5-14g/100g蛋白质物质。
25.权利要求5-24之任一项的组合物,其包含至少一种选自矿物质、微量元素和维生素的组分,所述组分优选选自维生素A、维生素C、维生素D、维生素E、维生素B6、维生素B1、维生素B2、生物素、硫辛酸、维生素B12和锌。
26.权利要求25的组合物,其包含叶酸,所述叶酸优选是游离叶酸、亚叶酸、甲酰化叶酸、甲基化叶酸的形式,更优选为还原形式或单谷氨酸缀合或多谷氨酸缀合衍生物的形式。
27.权利要求26的组合物,其中所述叶酸的含量为至少95μg/100kcal碳水化合物,优选110-400μg/100kcal碳水化合物,更优选125-300μg/100kcal碳水化合物。
28.权利要求25-27之任一项的组合物,其包含锌,所述锌的浓度优选为至少2.8mg/100kcal碳水化合物,更优选5.6-20mg/100kcal碳水化合物,更优选6-15mg/100kcal碳水化合物。
29.用于治疗罹患胰岛素耐受的个体的方法,其包括给药前述权利要求之任一项的组合物。
30.权利要求29的方法,其中所述治疗包括治疗由胰岛素耐受导致的肌肉分解代谢。
31.用于治疗由胰岛素耐受导致的肌肉分解代谢的方法,其包括向个体给药包含蛋白质部分的组合物,所述蛋白质部分提供所述组合物能量值的至少24.0%(en%)和基于蛋白质物质的至少12重量%的亮氨酸。
32.权利要求29、30或31的方法,其中所述组合物是权利要求5-28之任一项的组合物。
33.权利要求29-32之任一项的方法,其中所述个体是人。
34.权利要求29-33之任一项的方法,其用于治疗罹患至少一种选自代谢综合征,特别是糖尿病和/或肥胖;癌症;艾滋病;阿尔茨海默病;心力衰竭;和严重炎症病症,特别是慢性肺病;关节炎,特别是风湿性关节炎;炎性肠病的病症的个体。
35.权利要求34的方法,其中所述个体罹患II型糖尿病。
36.权利要求29-35之任一项的方法,其中所述组合物以液体形式给药。
37.权利要求29-36之任一项的方法,其中所述组合物以50-500g,优选75-400g,更优选100-250g的一份剂量给药。
38.权利要求29-37之任一项的方法,其中所述组合物经肠道给药。
39.权利要求1-28之任一项中定义的组合物用于改善生命质量,特别是用于改善不活动的人和/或老年人的生命质量的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05077339.9 | 2005-10-12 | ||
EP05077339 | 2005-10-12 | ||
EP05077579.0 | 2005-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101325951A true CN101325951A (zh) | 2008-12-17 |
Family
ID=36228553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800466429A Pending CN101325951A (zh) | 2005-10-12 | 2006-10-11 | 富含亮氨酸的组合物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080275120A1 (zh) |
EP (2) | EP1774973A1 (zh) |
JP (2) | JP2009511576A (zh) |
CN (1) | CN101325951A (zh) |
AU (1) | AU2006300046A1 (zh) |
BR (1) | BRPI0617358A2 (zh) |
CA (1) | CA2625819A1 (zh) |
IL (1) | IL190671A0 (zh) |
MX (1) | MX2008004734A (zh) |
RU (1) | RU2428977C2 (zh) |
WO (1) | WO2007043870A1 (zh) |
ZA (1) | ZA200803856B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102892309A (zh) * | 2010-03-26 | 2013-01-23 | N·V·努特里奇亚 | 增加必需氨基酸的低蛋白婴儿配方奶 |
CN103458891A (zh) * | 2011-04-13 | 2013-12-18 | 味之素株式会社 | 营养组合物 |
CN103491804A (zh) * | 2011-04-18 | 2014-01-01 | 雀巢产品技术援助有限公司 | 具有α-HICA 和二十碳五烯酸的营养组合物 |
CN105769844A (zh) * | 2016-05-25 | 2016-07-20 | 天津嘉氏堂医美科技有限公司 | 一种含精氨酸的组合物及制剂 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1774973A1 (en) * | 2005-10-12 | 2007-04-18 | Nutricia N.V. | Leucine rich composition |
WO2009157759A1 (en) * | 2008-06-23 | 2009-12-30 | N.V. Nutricia | Nutritional composition for improving the mammalian immune system |
WO2010002242A1 (en) * | 2008-07-02 | 2010-01-07 | N.V. Nutricia | Nutritional composition for improving muscle function and daily activity |
ITMI20081405A1 (it) * | 2008-07-29 | 2010-01-30 | Velleja Res Srl | Formulazioni orali istantanee, gelificanti a temperatura ambiente, utili per contrastare il deperimento organico e la sindrome depressiva connessi a cachessia, anoressia, malattia metabolica, malattia endocrina e disfagia |
WO2011078654A1 (en) * | 2009-12-24 | 2011-06-30 | N.V. Nutricia | Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis |
ES2667011T3 (es) | 2010-07-05 | 2018-05-09 | Beth Israel Deaconess Medical Center, Inc. | Monoacilgliceroles sn-2 y malabsorción lipídica |
WO2012005568A1 (en) | 2010-07-07 | 2012-01-12 | N.V. Nutricia | Nutritional composition for the stimulation of muscle protein synthesis |
JP2016513701A (ja) * | 2013-03-14 | 2016-05-16 | アボット・ラボラトリーズAbbott Laboratories | 長期身体不活動に関連するインスリン抵抗性の治療 |
CN112931879A (zh) | 2013-06-10 | 2021-06-11 | N·V·努特里奇亚 | 超重或肥胖成年人在体重减轻项目期间的肌肉保持 |
FR3015860B1 (fr) * | 2013-12-30 | 2019-08-16 | Pronokal Health Group, Sociedad Limitada | Composition alimentaire de regime pour diminuer l'inflammation de bas grade a court et long terme comprenant de l'acide docosahexaenoique |
EP4026546A1 (en) | 2016-09-09 | 2022-07-13 | Ajinomoto Co., Inc. | Prevention or remediation composition for dementia or depression |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
WO2019036471A1 (en) | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE |
AR115585A1 (es) | 2018-06-20 | 2021-02-03 | Axcella Health Inc | Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo |
CN113519850A (zh) * | 2020-04-13 | 2021-10-22 | 内蒙古蒙牛乳业(集团)股份有限公司 | 肿瘤全营养乳剂、其制备方法和用途 |
CN113582871B (zh) * | 2021-09-29 | 2022-01-04 | 北京天赋神奇科技有限公司 | 一种含镁水溶性欧米伽3脂肪酸 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4780475A (en) * | 1986-02-03 | 1988-10-25 | Cerra Frank B | Preparation for the prevention of catabolism |
US20010041187A1 (en) * | 1998-10-20 | 2001-11-15 | Carl W Hastings | Performance-enhancing dietary supplement |
US6890571B2 (en) * | 2002-05-14 | 2005-05-10 | National Starch And Chemical Investment Holding Corporation | Slowly digestible starch product |
WO2004000042A2 (en) * | 2002-06-19 | 2003-12-31 | N.V. Nutricia | Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
US20040087490A1 (en) * | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
US7037522B2 (en) * | 2002-09-27 | 2006-05-02 | Western Holdings, L.L.C. | Nocturnal muscle enhancing composition and method |
US7288570B2 (en) * | 2002-12-20 | 2007-10-30 | Nutricia N.V. | Stimulation of in vivo production of proteins |
US8697679B2 (en) * | 2003-03-07 | 2014-04-15 | N.V. Nutricia | Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
DE602004014275D1 (de) * | 2003-06-30 | 2008-07-17 | Nestec Sa | Zusammensetzung zur behandlung und/oder vorbeugung von insulinresistenz |
RU2633071C2 (ru) * | 2004-07-19 | 2017-10-11 | Н.В. Нютрисиа | Препарат для применения аспартата и витамина в12 или биотина для регуляции кетоновых тел |
EP1774973A1 (en) * | 2005-10-12 | 2007-04-18 | Nutricia N.V. | Leucine rich composition |
-
2005
- 2005-11-11 EP EP20050077579 patent/EP1774973A1/en not_active Withdrawn
-
2006
- 2006-10-11 WO PCT/NL2006/000515 patent/WO2007043870A1/en active Application Filing
- 2006-10-11 MX MX2008004734A patent/MX2008004734A/es active IP Right Grant
- 2006-10-11 AU AU2006300046A patent/AU2006300046A1/en not_active Abandoned
- 2006-10-11 RU RU2008118341/15A patent/RU2428977C2/ru not_active IP Right Cessation
- 2006-10-11 JP JP2008535476A patent/JP2009511576A/ja active Pending
- 2006-10-11 CA CA002625819A patent/CA2625819A1/en not_active Abandoned
- 2006-10-11 EP EP06799504A patent/EP1945199A1/en not_active Withdrawn
- 2006-10-11 CN CNA2006800466429A patent/CN101325951A/zh active Pending
- 2006-10-11 BR BRPI0617358-6A patent/BRPI0617358A2/pt not_active IP Right Cessation
-
2008
- 2008-04-07 IL IL190671A patent/IL190671A0/en unknown
- 2008-04-10 US US12/100,590 patent/US20080275120A1/en not_active Abandoned
- 2008-05-06 ZA ZA200803856A patent/ZA200803856B/xx unknown
-
2013
- 2013-03-21 JP JP2013058860A patent/JP2013139470A/ja active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102892309A (zh) * | 2010-03-26 | 2013-01-23 | N·V·努特里奇亚 | 增加必需氨基酸的低蛋白婴儿配方奶 |
CN102892309B (zh) * | 2010-03-26 | 2016-01-27 | N·V·努特里奇亚 | 增加必需氨基酸的低蛋白婴儿配方奶 |
CN103458891A (zh) * | 2011-04-13 | 2013-12-18 | 味之素株式会社 | 营养组合物 |
US10136669B2 (en) | 2011-04-13 | 2018-11-27 | Ajinomoto Co., Inc. | Method for decreasing visceral fat or increasing energy consumption |
CN103491804A (zh) * | 2011-04-18 | 2014-01-01 | 雀巢产品技术援助有限公司 | 具有α-HICA 和二十碳五烯酸的营养组合物 |
CN105769844A (zh) * | 2016-05-25 | 2016-07-20 | 天津嘉氏堂医美科技有限公司 | 一种含精氨酸的组合物及制剂 |
Also Published As
Publication number | Publication date |
---|---|
JP2009511576A (ja) | 2009-03-19 |
CA2625819A1 (en) | 2007-04-19 |
EP1774973A1 (en) | 2007-04-18 |
JP2013139470A (ja) | 2013-07-18 |
AU2006300046A1 (en) | 2007-04-19 |
WO2007043870A1 (en) | 2007-04-19 |
US20080275120A1 (en) | 2008-11-06 |
BRPI0617358A2 (pt) | 2011-07-26 |
MX2008004734A (es) | 2008-10-23 |
RU2428977C2 (ru) | 2011-09-20 |
ZA200803856B (en) | 2009-04-29 |
RU2008118341A (ru) | 2009-11-20 |
IL190671A0 (en) | 2008-11-03 |
AU2006300046A2 (en) | 2008-05-08 |
EP1945199A1 (en) | 2008-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101325951A (zh) | 富含亮氨酸的组合物 | |
EP2695528B1 (en) | Nutritional composition for improving muscle function and daily activity | |
EP1653981B1 (en) | Fish protein hydrolyzate | |
Ginguay et al. | Indications and contraindications for infusing specific amino acids (leucine, glutamine, arginine, citrulline, and taurine) in critical illness | |
JP2013515718A (ja) | 筋タンパク質合成を刺激するための低カロリー高タンパク質栄養組成物 | |
JP2023058496A (ja) | 肝疾患の治療のためのアミノ酸組成物 | |
US20100298437A1 (en) | Use of citrulline for treating undernutrition conditions | |
JPWO2006061992A1 (ja) | 肝疾患予防・治療用組成物 | |
JP2003171271A (ja) | 耐糖能異常用薬剤 | |
RU2372900C2 (ru) | Ингибитор возникновения и развития рака печени для применения у пациентов-людей с циррозом печени, положительных по вирусу гепатита с | |
US20100119499A1 (en) | Stilbene-based compositions and methods of use therefor | |
Amigo-Benavent et al. | The insulinotropic and incretin response to feeding a milk based protein matrix in healthy young women | |
JP6044667B2 (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
JP2008285463A (ja) | 関節症・リウマチ・膠原病の治療薬 | |
JP4715423B2 (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
JPS62126126A (ja) | 経腸栄養剤 | |
JP2518636B2 (ja) | 重症感染症及び広範囲熱症治療経腸栄養剤 | |
Farges et al. | Oral administration of a glutamine-enriched diet before or after endotoxin challenge in aged rats has limited effects | |
ES2528361T3 (es) | Agente antitumoral | |
JP7138565B2 (ja) | 心臓の代謝性に対するランタスの効果 | |
サメ軟骨のプロテアーゼ分解物に含まれる et al. | Study on uric acid lowering peptides in proteolytic digest of shark cartilage. | |
JP2006055022A (ja) | 肝硬変進展抑制用食品及び薬剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20081217 |